ÂÜÀòÂÒÂ×

Mark Dudley is currently the Chief Scientific Officer at Instil Bio, overseeing the research and development of Tumor Infiltrating Lymphocyte therapies. Prior to this role, Mark held senior positions at Adaptimmune US and Novartis, where Mark led teams in the development of cell and gene therapies. With a background in biological sciences and extensive experience in the field, Mark has a proven track record of translating bench discoveries into innovative patient therapies.